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Available online 09 February 2017The chronic shortage of human transplants to treat tissue and organ failure has led to the development of xeno-
transplantation, the transplantation of cells, tissues and organs from another species to human recipients. For a
number of reasons, pigs are best suited as donor animals. Successful, routine xenotransplantation would have
an enormous impact on the health of the human population, including the young, who sometimes require a re-
placement organ or islet cells, but especially the elderly,whomore often suffer the consequences of organ failure.
The first form of xenotransplantation applied to humans is the use of pig islet cells to treat insulin-dependent di-
abetes, a procedure that will have a significant economic impact. However, although xenotransplantation using
pig cells, tissues and organs may save and prolong the lives of patients, it may also be associated with the trans-
mission of porcinemicroorganisms to the recipient, eventually resulting in emerging infectious diseases. For this
reason, the health of both the donor animals and the human recipients represents a special and sensitive case of
the One Health concept. Basic research leading to strategies how to prevent transmission of porcinemicroorgan-
isms by selection of virus-free animals, treatment of donor pigs by antiviral drugs, vaccines, colostrum depriva-
tion, early weaning, Caesarean delivery, embryo transfer and/or gene editing should be undertaken to supply
an increasing number of potential recipients with urgently required transplants. The methods developed for
the detection and elimination of porcinemicroorganisms in the context of xenotransplantation will also contrib-
ute to an improvement in the health of pig populations in general and an increase in the quality ofmeat products.
At present, there is evidence for transmission of porcine viruses to humans eating pork and having contact with
pigs, however the impact of these viruses on public health is still unknown.er 20, D-13353 Be
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Due to the increase in life expectancy of the human population, in-
creasing numbers of people suffer from tissue and organ failure that
can, in most cases, only be treated by transplantation of cells, tissuesrlin, Germany.
ccess article underor organs. However, the number of human transplants available is insuf-
ficient to treat all patients in need. For example, in the USA there are
more than 122,000 people waiting for much-needed organs [1] and an
average of 22 people in the USA die each day while waiting for a trans-
plant. Xenotransplanation using pig cells, tissues or organs may help
overcome this shortage of human materials.
Furthermore, the number of patients with diabetes mellitus type 1
(insulin-dependent diabetes) is increasing world-wide [2]. Despite thethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
18 J. Denner One Health 3 (2017) 17–22ability to treat the disease with insulin (derived for decades from pigs)
the highest economic burden results from serious and potentially life-
threatening complications [3]. Xenotransplantation using porcine islet
cells would allow physiological regulation of the insulin production
and is considered to be a promising approach to treat type 1 diabetes.
An alternative therapy using pluripotent stem cells or committed cells
and cellular reprogramming is at present only at the beginning of devel-
opment [4].
2. Safety aspects of allotransplantation and xenotransplantation
Despite the potential to save and prolong lives, xenotransplantation
using pig cells, tissues and organs can be associated with the transmis-
sion of potentially zoonotic porcine microorganisms. In this context, it
is well known that allotransplantation has been associated with the
transmission of viruses and other microorganisms to the recipient, in-
cluding viruses such as the human immunodeficiency virus 1 (HIV-1),
human hepatitis B and hepatitis C viruses, rabies virus, West Nile
virus, hepatitis E virus (HEV), human cytomegalovirus, bacteria such
as Trepanoma pallidum, fungi such as Aspergillus and many others as
well as parasites [4–17]. The future development of pigs free of poten-
tially zoonotic porcine microorganisms would render xenotransplanta-
tion a considerably safer technology comparedwith allotransplantation.
Evaluating the benefit/risk ratio of xenotransplantation means to esti-
mate the benefit coming from the survival with a well-functioning
organ on one hand, and the risk of transmission of porcinemicroorgan-
isms including bacteria, fungi, and viruses to the recipient on one hand.
Therefore and independent from the fact, that the national and regional
regulations covering the microbiological screening of donors for allo-
transplantation, as well as the microbiological assays available, varies
considerably, the rules governing xenotransplantation need to be devel-
oped [18,19].
Humanpathogens that can be transmitted by allotransplantation are
in most cases well characterised, for example HIV-1, HEV, rabies virus,
and sensitive detection methods are generally available. However, in
the case of xenotransplantation, the potentially zoonotic microorgan-
isms remain partially unknown and sensitive detection methods are
under development. There are indeed a lot of veterinary diagnostic lab-
oratories with assays for infectious disease monitoring in pig herds,
however their assays are usually monitoring pig diseases with high im-
pact onmeat production. Based on earlyfindings showing that somede-
tection methods are not sensitive enough [20], new and improved
methods for potentially zoonotic microorganisms are under develop-
ment. There is evidence that some porcine viruses are able to infect
human cells in vitro or humans in vivo, e.g., HEV. Whereas the microor-
ganisms transmitted after allotransplantation are adapted to humans,
many porcine microorganisms fail to infect humans due to the innate
and adaptive immune response, due to the absence of suitable receptors
on human cells or due to human intracellular restriction factors.
Restriction factors are cellular proteins that inhibit viral replication
and represent a first line of defense against viral pathogens [21]. They
show an enormous structural and functional diversity and target nearly
every step if the viral replication cycle. Examples of such restriction fac-
tors are APOBEC3 (apolipoprotein B mRNA editing enzyme catalytic
polypeptide 3), which induces hypermutation by deamination, or
tetherin, which prevents virus release by tethering budding progeny vi-
rions to the plasma membrane of the infected cell [21]. Bacteria, fungi,
parasites and viruses are potentially zoonotic porcine microorganisms.
Whereas bacteria and fungi can be treated and eliminated by antibiotics
and antifungals, treating viral infections with antivirals is more compli-
cated and it seems that therefore viruses represent a greater risk.
Among the potentially zoonotic viruses, porcine endogenous retrovi-
ruses (PERVs), porcine cytomegalovirus (PCMV), HEV genotype 3, por-
cine lymphotropic herpesviruses (PLHV), and porcine circoviruses
(PCV) are the best characterised (Table 1). Whereas PCMV, HEV,
PLHV, PCV as well as bacteria and fungi may be eliminated from pigsusing different methods, this is impossible with PERVs, since these vi-
ruses are integrated into the genome of all pigs (for review see [22]).
It is important to note that processing, transport and manufacture
processes of the potential transplant should be performed so that no ad-
ditional microorganisms will be introduced.
3. Detection methods and elimination programs
Sensitive detection methods and refined detection strategies are re-
quired to detect potentially zoonotic porcine microorganisms and ex-
clude infected pigs from the herds. Recently, detection of PCMV in
Göttingen Minipigs was reported when using sensitive, but not when
using less sensitive methods [20]. Since it is unclear whether PCMV
can infect humans in general or whether a minimal amount of virus
(threshold) is required, it remains unclear how sensitive the detection
methods should be. On the other hand, despite using sensitivemethods,
PCMV was not detected in the blood of two donor pigs, but later in the
blood of two non-human primate recipients ([23], Denner et al., unpub-
lished). Therefore, in addition to sensitive methods also new testing
strategies should be developed, e.g., testing other samples such as oral
and anal swabs, ear biopsies or organs. Screening 10 days old piglets
for PCMV, virus was more effectively detected using oral and anal
swabs in comparison to blood samples [24]. The sensitive assays may
also be used to screen the human recipients of xenotransplants but
only in the case the donor pigs were positive. There is no need to screen
the recipientwhen the donor pigs were negative. Most importantly, the
improved and sensitive detection methods developed for xenotrans-
plantation can be used to screen pig herds bred for meat production in
order to increase the quality and safety of pork products. For some por-
cinemicroorganisms,methods that directly detect their DNAor RNAge-
nomes by PCR, that measure proteins or virus particles using specific
antibodies or that measure infectious viruses using infection assays
have recently been developed. The readout of such infection assays
may involve detection of virus by PCR or detection of genome expres-
sion at the mRNA or protein level. Indirect detection methods are
based on measuring humoral immune responses induced by infection
using common methods such as ELISA or Western blot analysis. These
methods require virus-specific antigens, either purified virus particles
or recombinant viral proteins, and, if possible, positive control sera pro-
duced in goats, rats or other animals against purified virus antigens. Im-
munological detection methods (Western blot assays, ELISAs) have the
advantage that they can determine virus infection even when the virus
is undetectable by PCRmethods. Prerequisite of successful immunolog-
ical assays are well characterised antigens such as purified recombinant
viral proteins or purified viruses, not lysates of infected cells. Unless it is
impossible to discriminate between viral latency and elimination of the
virus by the immune response, antibody-positive animals should not be
used as donors for xenotransplantation. Highly sensitive PCR-based
and immunological methods have already been developed for PERVs
([for review see [22]), PCMV [25–29], HEV genotype 3 [30–35], PCV2
[36–38] and PLHV1, 2, 3 [39,40] in some specialised laboratories and
there is hope that they will be used and improved in future in many
test laboratories. As mentioned above, sensitive methods are the pre-
requisite for an effective detection of PCMVwhereas detectionmethods
of low sensitivity failed [20]. Since the virus load is often extremely low
and the viruses may be latent and/or hidden in specific organs making
them difficult to detect, new screening strategies should be developed.
Important in this context is also the time of testing. In the case the
virus is going latent, detection may be easy immediately after infection.
In contrast, in the case the virus is replicating, the highest probability to
detect it, is immediately before transplantation. Possible approaches to
eliminate specific porcine microorganisms, apart from selection of
negative animals, include treatment of infected animals with antiviral
drugs and prevention of infection by vaccination. Unfortunately, for
many potential pathogens, neither antiviral drugs nor vaccines are cur-
rently available [14,41–43]. In addition, Caesarean section, colostrum
Table 1
Selected porcine microorganisms with zoonotic potential.




Possible consequences in the recipient References
PCMV Immunosuppression, fatal
disease in newborn pigs
Unknowna Unknown Transplant rejection For review see Denner [41]; Yamada et al.
[55]; Sekijima et al. [56]
PCV2 Yesb Yes No Unlikelyc For review see Segales et al. [103]
HEV Transient febrile illness Yes Yes Liver disease or asymptomatic For review see Denner, [14]; Meng et al.
[64]; Schlosser et al. [104]
PERV Unknown Yesd Unknown Unknown, theoretically retroviruses may induce
tumours, immunodeficiencies or may be
apathogenic
For review see Denner and Toenjes [22]
a Infection of human fibroblasts was reported (Whitteker et al. [105]), but also lack of infection of different human cells (Tucker et al. [106]).
b Postweaning multisystemic wasting syndrome (PMWS), PCV2 disease (PCVD), PCV2-systemic disease (PCV2-SD, directly replacing PMWS), PCV2-subclinical infection (PCV2-SI),
PCV2-reproductive disease (PCV2-RD), porcine dermatitis and nephropathy syndrome (PDNS).
c Contamination of vaccines against rotaviral gastroenteritis from two differentmanufacturerswith PCV1 and PCV2 did not result in PCV-infection of the vaccinees (Gilliland et al. [107];
McClenahan et al. [108]; Baylis et al. [109]; Dubin et al. [110]).
d Infection was observedmainly with tumor cells lacking APOBEC (for review see Denner and Tönjes [22]), but infection of primary cells with human-adapted PERVwas also observed
(Denner [111]).
19J. Denner One Health 3 (2017) 17–22deprivation, early weaning and clean embryo transfer are effective ap-
proaches in eliminating infectious pathogens from the herd [29,44–46].
The most important part of all elimination programs is isolation of the
clean animals to avoid de novo infection.
The situation with PERVs is more complicated, as these are integrat-
ed as DNA copy into the pig genome and are able to infect human cells
(for review see [22]). Since each pig genome carries multiple copies of
PERV proviruses, gene editing may be the best approach to inactivate
them. Attempts at gene editing using the zinc finger nuclease (ZFN) re-
sulted in very high expression of the ZFN to toxic levels, presumably a
result of cutting the genome at multiple sites and destabilising it [47].
However, when the recently developed CRISPR/Cas9 (clustered regular-
ly interspaced short palindromic repeats/CRISPR-associated) technolo-
gy was applied, 62 PERV proviruses were successfully knocked-out in
immortalised PK-15 pig cells [48]. It remains to be seen whether it
will be possible to knock-out all PERV proviruses in primary cells and
to use these to obtain healthy PERV-free piglets [49].
4. Recent achievements in xenotransplantation
In recent years remarkable achievements have been reported in the
various different fields of xenotransplantation. First, genetically
modified pigs expressing multiple human genes and with knock-outs
of pig genes responsible for hyperacute rejection have been generated
[50,51]. Second, these genetic modifications in combination with new
immunosuppressive regimens resulted in longer survival times in
preclinical pig-to-nonhuman primate xenotransplantions compared to
earlier attempts (Table 2) [52–54]. In these trials neither PERVs norTable 2
Recent achievements in preclinical xenotransplantation: Longest survival times, 2016.a
Transplant Recipient Longest survival time
(days)
Remarksb
Islet cells Rhesus |600 Non-transgenic pigs used
Kidney Baboon 136 Life-supporting
GTKO:CD46:CD55:hTM:CD39:blood type 0
(non-A)d
Heart Baboon 945 Heterotopic
GTKO:CD46:hTM
Liver Baboon 25 GTKO
PCMV-negative
a For details and previous trials see Cooper et al. [54] and Denner et al. [55].
b GTKO, α-galactosyltransferase knockout¸CD39, endothelial protein C receptor; CD46, mem
thrombomodulin.
c ATG, anti-thymocyte globulin; belatacept, fusion protein composed of the Fc fragment of a
venom factor; FK-506, tacrolimus; MMF, mycophenolate mofetil; octaplex, human prothrombi
d hTM and hCD39 were not expressed in the kidney.
e In addition anti-inflammatory (tocilizumab, IL-6 receptor blockade, etanervept, TFN-a antaother porcine microorganisms were transmitted (for review see
[22,54]). In contrast, transplantations of pig PCMV-infected kidneys
to baboons [55] or cynomolgus monkeys [56] were associated with
a dramatically reduced survival time of the transplants compared with
transplantations of uninfected kidneys. In the transplant a high titer of
PCMV was found. High virus titers were also observed in the blood of
two baboons after orthotopic pig heart transplantation ([23], Denner
et al., unpublished data). There is clear evidence that PCMV was trans-
mitted by the transplanted heart to the recipient. However, it is still un-
clear whether the virus established infection in cells of the primate host
or whether it remained restricted to the cells of the transplant. Based on
these results and the experiencewith human CMV in human transplant
recipients [57], itmay be suggested that PCMVmay be similarly harmful
for human recipients. At present it is unclear whether PCMV can infect
human cells or cells from non-human primates or whether the
pathogenic effect observed in non-human primates is due to indirect
effects. Third, with regard to microbiological safety, pigs are being
analysed in more detail and programs to eliminate potentially zoonotic
microorganisms have been proposed (see above). Fourth, clinical
xenotransplantations have now been performed in New Zealand and
in Argentina that resulted in a low medical benefit, but transmission
of porcine microorganism was not observed [58–61]. Although reduc-
tion in HbA1c (glycated hemoglobin which is a form of hemoglobin
that is measured primarily to identify the three-month average plasma
glucose concentration) and insulin doses were marginal, the efficacy in
the first trial was assessed by calculating the transplant estimated factor
(TEF), which indicated in all cases a low transplant function and only in
one case full graft function [58,60]. In the second clinical trial the HbA1cImmunosuppressionc References
CVF, ATG, anti-CD154, sirolimus Shin et al. [112]
ATG, anti-CD20mAb, CVF, anti-CD40mAb, rapamycin, MPe Iwase et al. [113]
ATG, anti-CD20mAb, anti-CD40mAb, CVF, MMF, steroid Mohiuddin et al. [114]
Octaplex, thymoglobolin, CVF, belatacept, FK-506,
methylprednisone
Shah et al. [115]
brane cofactor protein; CD55, complement decay-accelerating factor, DAF; hTM, human
human IgG1 immunoglobulin linked to the extracellular domain of CTLA-4 CVF, cobra
n complex.
gonist) and adjunctive (aspirin, low molecular weight heparin) treatment.
20 J. Denner One Health 3 (2017) 17–22was reduced to less than 7% and the average TEF indicated partial trans-
plant function [60].
5. Impact on animal and public health
Themethods developed for xenotransplantation to screen pig donors
and human recipients can also be used to screen pigs bred for meat pro-
duction. The prevalence of some viruses is very high in most pig popula-
tions. For viruses causing economically important diseases in pigs, such as
porcine reproductive and respiratory syndrome virus (PRRSV) and PCV2,
sensitive detection methods and effective vaccines have been developed
und successfully employed [62]. Theremay be viruses and othermicroor-
ganisms present in the pigs which obviously do not harm the pig, but
may be zoonotic for the human recipient, for example PCMV and HEV.
85% of pigs in a slaughterhouse in the Berlin area were found to be
PCMV-positive [63]. HEV is a good example that pig viruses can be easily
transmitted to humans and that they therefore pose a risk for xenotrans-
plantation [14,64,65]. Pigs are infected with HEV genotype (gt) 3 and gt4
[14,64–66] (not to be confused with HEV gt1 and gt2, which are only
found in humans and which can cause infections with fatalities ap-
proaching 25% in pregnant women). The main route of infection with
HEV gt3 is food-borne transmission, e.g., contact with contaminated
meat, or by direct contact with infected animals [67–72], by shellfish
[73,74],but also by vegetables (probably contaminated with pig manure)
[75], blood transfusion [76–78] and allotransplantation [79–82]. Most in-
fections with HEV gt3 and gt4 are asymptomatic, whereas severe hepati-
tis occurs only in combination with other pre-existing chronic liver
diseases. In addition, chronic infectionwith HEV ismore likely to develop
in profoundly immunosuppressed patients, for example during chemo-
therapy [83] and HIV infection [84,85]. Patients undergoing xenotrans-
plantation will certainly require immunosuppression. In Germany, the
HEV seroprevalence of domestic pigs varied between 42.7% and 64.8%
[86,87], and genomic HEVRNAwas found in 22% of pig liver sausages (al-
though infectivitywas not tested in this case) [88]. Antibodies specific for
HEV were found in 67% of older hunters and in 17% of the general popu-
lation [89,90]. Although the impact of HEV infections on the health of in-
fected human individuals and on public health in general is unknown, it
may be assumed that detection of HEV in domestic pigs using the sensi-
tive methods developed for xenotransplantation and the selection of
virus-free animals will prevent infection of humans. This raises the ques-
tion of whether the expense of eliminating HEV from pig herds might be
lower than the direct and indirect costs ofmedical treatments for infected
individuals. In addition, as elimination of HEV from pigs prevents infec-
tion of humans, it would also prevent transmission by blood transfusion.
Evaluating the potential risk associated with xenotransplantation
using pig cells, tissues and organs requires also an analysis of epidemio-
logical data comparing diseases in individuals eating red meat (beef,
pork, lamb, veal, mutton) and vegetarians. The International Agency
for Research on Cancer classified consumption of red meat as “probably
carcinogenic to humans” and of processed red meat as “carcinogenic to
humans” based on the assessment of more than 800 epidemiological
studies in many countries, different continents, with diverse ethnicities
and diets [91]. Other studies came to the same or slightly different re-
sults [92–100]. At present it is impossible to determine whether pig
meat transmits tumor-inducing viruses or other infectious agents to
customers, whether these results are due to chemical carcinogens or
both. It is also unknown which impact such infectious agents may
have on xenotransplantation if they indeed exist. Interestingly, replica-
tion-competent circular DNA molecules were described in serum and
milk from healthy cattles and an association of milk and beef with can-
cer and multiple sclerosis was suggested [101,102].
6. Conclusion
Naturally occurring emerging infectious diseases continue to impose
an enormous burden on global health and economy. Therefore it isimportant to avoid producing new diseases when using pig cells, tissues
or organs to treat humandiseases. The development of sensitivemethods
to detect porcine microorganisms in donor pigs is a prerequisite in order
to select negative animals and to prevent transmission to the transplant
recipients. The same detection methods may also be used to monitor
the recipient (although, obviously, if the microorganism in question has
been eliminated from the donor pig, there would be no need to test the
recipients). Finally, using these same detection methods developed for
xenotransplantation to screen pigs bred for meat production will allow
to select virus-free animals and to eliminate these microorganisms from
the herd and to improve the health of the animals. This would prevent
transmission bymeat eating and contact andprevent the clinical and sub-
clinical infections that may have an enormous impact on public health.
Therefore, research on the microbiological safety of xenotransplantation
may eventually improve animal health and public health and should be
a task for all Public Health Institutes.
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